These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 27530266)

  • 1. Overactive bladder in children.
    Franco I
    Nat Rev Urol; 2016 Sep; 13(9):520-32. PubMed ID: 27530266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric overactive bladder syndrome: pathophysiology and management.
    Franco I
    Paediatr Drugs; 2007; 9(6):379-90. PubMed ID: 18052408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
    Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
    J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of OAB in those over age 65.
    Natalin R; Lorenzetti F; Dambros M
    Curr Urol Rep; 2013 Oct; 14(5):379-85. PubMed ID: 23922134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive Bladder.
    White N; Iglesia CB
    Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
    Yüce T; Dökmeci F; Çetinkaya ŞE
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder.
    Fukui S; Aoki K; Morizawa Y; Miyake M; Fujimoto K
    Urology; 2017 May; 103():214-217. PubMed ID: 28161379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrical nerve stimulation for overactive bladder in children.
    Barroso U; Lordêlo P
    Nat Rev Urol; 2011 Jun; 8(7):402-7. PubMed ID: 21647183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder.
    Chung E; Lee D; Gani J; Gillman M; Maher C; Brennan J; Johns Putra L; Ahmad L; Chan LL
    Med J Aust; 2018 Jan; 208(1):41-45. PubMed ID: 29320672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature.
    Kasman A; Stave C; Elliott CS
    Neurourol Urodyn; 2019 Nov; 38(8):2083-2092. PubMed ID: 31483070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2019 Sep; 11(4):177-181. PubMed ID: 30900373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
    Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
    Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates of Overactive Bladder in Pediatrics.
    Shim J; Oh MM
    Int Neurourol J; 2023 Mar; 27(1):3-14. PubMed ID: 37015720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vulnerable elderly patients and overactive bladder syndrome.
    Kraus SR; Bavendam T; Brake T; Griebling TL
    Drugs Aging; 2010 Sep; 27(9):697-713. PubMed ID: 20809661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urinary incontinence: what's new in therapy?].
    Becher KF; Sieber CC
    Dtsch Med Wochenschr; 2015 Feb; 140(3):164-7. PubMed ID: 25658400
    [No Abstract]   [Full Text] [Related]  

  • 20. The challenge of overactive bladder therapy: alternative to antimuscarinic agents.
    Lazzeri M; Spinelli M
    Int Braz J Urol; 2006; 32(6):620-30. PubMed ID: 17201939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.